Edit
Personal Genome Diagnostics (PGDx)
http://www.personalgenome.com/Last activity: 05.08.2021
Active
Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.
Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.
PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.
Named a 2019 Top Workplace by The Baltimore Sun
Named a 2018 winner of the Best Place to Work by the Business Intelligence Group
Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.
PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.
Named a 2019 Top Workplace by The Baltimore Sun
Named a 2018 winner of the Best Place to Work by the Business Intelligence Group
Location: United States, Maryland, Baltimore
Employees: 51-200
Total raised: $202.2M
Founded date: 2010
Investors 6
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | PFM Health... | pfmhealths... |
| - | Johns Hopk... | ventures.j... |
| - | 3B Future ... | 3bfuturehe... |
| - | Catalio Ca... | cataliocap... |
| - | Helsinn In... | helsinninv... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 10.02.2021 | Series C | $103M | - |
| 04.01.2018 | Series B | $75M | - |
| 02.11.2015 | Series A | $21.4M | New Enterp... |
| 02.04.2014 | - | $2.8M | - |
Mentions in press and media 24
| Date | Title | Description |
| 05.08.2021 | Power Moves: Baltimore’s Julius Valentine Maina joins accelerator gener8tor as chief of staff | Power Moves is a column where we chart the comings and goings of talent across the region, and other people-oriented updates. Got a new hire, new gig or promotion? Tell us: baltimore@technical.ly. Startup accelerator and VC fund gener8tor r... |
| 11.06.2021 | Power Moves: Catalyte expands the C-suite with growth in digital services | Power Moves is a column where we chart the comings and goings of talent across the region, and other people-oriented updates. Got a new hire, new gig or promotion? Tell us: baltimore@technical.ly. Catalyte, the Otterbein-based company that ... |
| 12.02.2021 | Daily funding roundup - February 11th, 2021 | Zocdoc raised $150M; Modern Health landed $74M; Human Interest secured $55M; WireWheel picks up $20M Zocdoc: Zocdoc is a digital healthcare scheduling platform. Zocdoc has raised $150 million in fresh funding led by Francisco Partners. Read... |
| 10.02.2021 | Personal Genome Diagnostics raises $103M to take cancer test kits global | Canton-based Personal Genome Diagnostics (PGDx) raised $103 million in a Series C round, providing new growth capital after the cancer genomics company received FDA approval for its diagnostic kit product last year. The financing was led by... |
| 10.02.2021 | Personal Genome Diagnostics Closes $103 Million Series C | BALTIMORE, Md.--(BUSINESS WIRE)--Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the close of a $103 million Series C financing. The financing was led by Cowen Healthcare Investments and joined by new a... |
| 27.04.2020 | NEA-backed Personal Genome Diagnostics receives FDA clearance for its cancer diagnostic | Personal Genome Diagnostics, the venture-backed developer of a novel diagnostic kit for genomic profiling of different cancers in lab settings, has received clearance from the U.S. Food and Drug Administration for its PGDx elio tissue compl... |
| 15.01.2020 | FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing | → Months after the UK’s cost-effectiveness agency NICE had a change of heart on its drug Rubraca — Clovis has announced that the FDA granted priority review for its application to expand the use of the drug to patients with... |
| 10.09.2019 | Another study shows liquid biopsy can detect cancer immunotherapy biomarker | “Microsatellite instability and high tumor mutation burden are promising pan-tumor biomarkers that are used to identify patients who may be candidates for treatment with immune checkpoint blockade,” PGDx vice president for translational med... |
| 05.10.2018 | Term Sheet — Friday, October 5 | YALE MONEY Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Yale University, which boasts the second-largest endowment in higher education, is among investors that helped a new fund focuse... |
| 04.10.2018 | Personal Genome Diagnostics gets new investment for cancer test development | Canton-based Personal Genome Diagnostics received its second investment in a year that could total in the tens of millions. New York–based investment firm Innovatus Capital Partners announced a capital infusion into the Johns Hopkins spinou... |
Show more